CRBU Caribou Biosciences, Inc.
USHealthcareAs of 2026-08-24
Why CRBU matters now
Caribou Biosciences, Inc. (CRBU) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.64 with -1.20% on the session and $162.7M in market capitalization; recent performance reads 1-month -16.75% and YTD +3.14%.
The latest financial table shown here is Q1 2026, with revenue of $2.4M, net income of $-25.1M, and EPS of $-0.26. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -62.5%.
The latest indexable market news headline is "Brokerages Set Caribou Biosciences, Inc. (NASDAQ:CRBU) Price Target at $7.75" from Defense World.
Additional event context on this page matters because analyst consensus is Buy with a median target of $5.00; recent insider activity includes Kelly Timothy P filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.54
P/S
14.52
EV/EBITDA
-1.59
DCF Value
$-2.74
FCF Yield
-62.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
82.6%
Operating Margin
-1175.7%
Net Margin
-1189.1%
ROE
-100.1%
ROA
-89.4%
ROIC
-100.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $2.4M | $-25.1M | $-0.26 |
| Q4 2025 | $3.9M | $-26.5M | $-0.28 |
| FY 2025 | $11.2M | $-148.1M | $-1.59 |
| Q3 2025 | $2.2M | $-27.5M | $-0.30 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$5.00
Target (Median)
$5.00
Target Range
$3.00 - $7.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
2.33
Caribou Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to pioneering genome-edited allogeneic cell therapies. These cutting-edge treatments are engineered to address both hematologic malignancies (blood cancers) and solid tumors, serving patients across the United States and internationally. Among its primary therapeutic candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy currently undergoing Phase 1 clinical trials for relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011, an allogeneic anti-BCMA CAR-T cell therapy targeting relapsed or refractory multiple myeloma. Caribou Biosciences is additionally developing CB-012, an allogeneic anti-CD371 CAR-T cell therapy for relapsed or refractory acute myeloid leukemia, along with CB-020, an allogeneic CAR-NK cell therapy aimed at solid tumors. The company also maintains a collaborative agreement with AbbVie Manufacturing Management Unlimited Company for the joint advancement of CAR-T cell therapies. Founded in 2011, Caribou Biosciences' headquarters are located in Berkeley, California.